Home > Health & Beauty > Optical
Optical
Altheos Announces Initiation of Phase 2a Clinical Trial for its Lead Glaucoma Drug Candidate, ATS907
February 09, 2012 17:30
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Altheos, Inc., announced today the dosing of the first patient in a Phase 2a clinical trial of its lead investigational candidate, ATS907, a Rho kinase (ROCK)-selective inhibitor in development as a next-generation eye drop for the reduction of elevat...




